CHS-114, a cytolytic anti-CCR8 antibody, reduced intratumoral CCR8+ Tregs by 74% and total FOXP3+ Tregs by 43%, while increasing CD8+ T-cell density by 73% and expanding the CD8/CCR8+ Treg ratio 12-fold in paired tumor biopsies from head and neck squamous cell carcinoma patients. Peripheral biomarker readouts showed sustained increases in CD8 activation and proliferation and Th1 cytokines, with stronger signals when combined with toripalimab. Safety to date appears manageable, and the program has reported early antitumor activity, including at least one partial response in the combination arm.
The update comes from a Phase 1/1b dose-expansion analysis in recurrent/metastatic HNSCC evaluating CHS-114 as monotherapy and with toripalimab. Multiomic profiling encompassed blood from 10 monotherapy and 6 combination patients, and paired tumor biopsies from 10 monotherapy patients and 2 on combination therapy, establishing proof of mechanism and pharmacologic activity at two dose levels. A dose-optimization arm is now enrolling up to 40 second-line HNSCC patients on the CHS-114–toripalimab combination to select a Phase 2 dose under a Project Optimus–aligned framework. A parallel Phase 1b/2a is extending the combination into colorectal, gastric, and esophageal cancers.
Strategically, Coherus is leaning into a tumor-selective Treg-depletion thesis to restore responsiveness to PD-1 blockade while minimizing the systemic immunotoxicity that has constrained earlier Treg-targeted approaches. The company’s ability to pair CHS-114 with its own PD-1, toripalimab, tightens control over dosing, supply, and study design, and concentrates value in proprietary combinations. The emphasis on pharmacodynamic endpoints signals a deliberate effort to meet the FDA’s early dose-optimization expectations, potentially shortening the path to a definitive efficacy test. The readout also positions Coherus within a small but active field exploring CCR8 as a tumor-restricted Treg marker; differentiation will hinge on the consistency of intratumoral depletion, the magnitude of CD8 remodeling, and the tolerability of sustained Treg removal in combination settings.
Operationally, this is a biopsy-heavy program. Mandatory paired tumor sampling and serial blood draws increase screen failures, site workload, and reliance on central labs, digital pathology, and complex flow/IHC pipelines. Sites with established biopsy logistics and interventional radiology capacity will be advantaged; others may struggle with scheduling, tissue adequacy, and assay turnaround that can slow cycle times. For CROs, the multiomic design ups the coordination burden across vendors and heightens the importance of specimen chain-of-custody and preanalytic standardization. Sponsors watching the Project Optimus implementation will note the use of mechanistic biomarkers to justify dose selection rather than traditional MTD logic, which could serve as a template for other cytolytic antibodies.
What matters next is translating immune remodeling into durable clinical benefit in PD-1–exposed, second-line HNSCC. The current tumor sample size for the combination is minimal, so the reproducibility of depletion and CD8 expansion at scale will be scrutinized, alongside any autoimmune signal as exposure accumulates. Expect increasing focus on baseline CCR8+ Treg burden as a potential enrichment marker, on durability of response and DCR as early efficacy anchors, and on whether CHS-114 can rescue PD-1 refractory disease. Manufacturing consistency for afucosylated ADCC antibodies, drug–drug interaction dynamics with PD-1 blockade, and competitive timing versus other CCR8 entrants are additional variables. If the dose-optimization arm delivers a clean safety profile, confirmatory pharmacodynamic data, and a credible ORR, the program could move quickly into a controlled Phase 2 in HNSCC, with GI tumor data informing a broader combination strategy.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
